On Wednesday, October 17, 2012, Abbott Laboratories (NYSE:ABT) is expected to release its third quarter earnings.

Investors care about earnings because they drive stock prices. Strong earnings generally result in the stock price moving up and vice versa. SEE: How To Decode A Company's Earnings Reports

What to Expect: Analysts are expecting Abbott to report earnings of $1.28 per share, up 8.5% from a year ago, when the company reported earnings of $1.18 per share.

Though it hasn't changed in the last month, the consensus estimate is up from $1.27 three months ago. For the fiscal year, analysts are projecting earnings of $5.06 per share.

Revenue is expected to exceed last year's figure of $9.82 billion by 1% and come in at $9.91 billion for the quarter. The anticipated revenue for the fiscal year is $39.75 billion.

Company Performance: In the past four quarters, revenue has shown consistent growth. It increased 2% to $9.81 billion in the second quarter. Prior to that, the figure rose 4.6% in the first quarter, 4.1% in the fourth quarter of the last fiscal year and 13.2% in the third quarter of the last fiscal year.

ABT's P/E ratio of 22.8 is above the industry average of 14.53. Usually, if a stock has a high P/E ratio, it indicates that the market expects the company to grow earnings quickly in the future. A company's price/earnings ratio (P/E ratio) provides a measure of how expensive or cheap a stock is. A high P/E ratio indicates a stock that is expensive, while a low P/E ratio indicates a stock that is cheap. SEE: Can Investors Trust the P/E Ratio?

The stock price has increased from $65.48 on July 16, 2012 to $69.42 over the past quarter. Currently, Abbott's stock is on a downward trend. The share price has fallen $2.19 since October 5, 2012.

The Competition: Abbott Laboratories is a pharmaceuticals health care company, whose main line of business is in the discovery, development, manufacture, and sale of a broad range of health care products. Its customers include wholesalers, hospitals and commercial laboratories. The company's closest competitor in the biotechnology and drugs industry, Johnson & Johnson (JNJ), will report earnings on October 16, 2012. Analysts are expecting earnings of $1.21 per share for Johnson & Johnson, down 2.4% from last year's earnings of $1.24 per share. Analysts are less optimistic about Abbott than about Johnson & Johnson. Fourteen out of 22 analysts rate the latter a buy compared to six of 18 for the former.

Related Articles
  1. Stock Analysis

    Allstate: How Being Boring Earns it Billions (ALL)

    A summary of what Allstate Insurance sells and whom it sells it to including recent mergers and acquisitions that have helped boost its bottom line.
  2. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  3. Investing Basics

    How to Deduct Your Stock Losses

    Held onto a stock for too long? Selling at a loss is never ideal, but it is possible to minimize the damage. Here's how.
  4. Economics

    Is Wall Street Living in Denial?

    Will remaining calm and staying long present significant risks to your investment health?
  5. Stock Analysis

    When Will Dick's Sporting Goods Bounce Back? (DKS)

    Is DKS a bargain here?
  6. Investing News

    How AT&T Evolved into a Mobile Phone Giant

    A third of Americans use an AT&T mobile phone. How did it evolve from a state-sponsored monopoly, though antitrust and a technological revolution?
  7. Stock Analysis

    Home Depot: Can its Shares Continue Climbing?

    Home Depot has outperformed the market by a wide margin in the last 12 months. Is this sustainable?
  8. Stock Analysis

    Yelp: Can it Regain its Losses in 2016? (YELP)

    Yelp investors have had reason to be happy recently. Will the good spirits last?
  9. Stock Analysis

    Is Walmart's Rally Sustainable? (WMT)

    Walmart is enjoying a short-term rally. Is it sustainable? Is Amazon still a better bet?
  10. Stock Analysis

    GoPro's Stock: Can it Fall Much Further? (GPRO)

    As a company that primarily sells discretionary products, GoPro and its potential falls right in line with consumer trends. Is that good or bad?
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center